$558 Million is the total value of Rock Springs Capital Management LP's 78 reported holdings in Q2 2014. The portfolio turnover from Q1 2014 to Q2 2014 was - .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| MRK | New | MERCK & CO INC NEW | $27,479,000 | – | 475,000 | +100.0% | 4.93% | – |
| MDT | New | MEDTRONIC INC | $26,460,000 | – | 415,000 | +100.0% | 4.74% | – |
| CI | New | CIGNA CORPORATION | $8,737,000 | – | 95,000 | +100.0% | 1.57% | – |
| HRC | New | HILL ROM HLDGS INC | $8,094,000 | – | 195,000 | +100.0% | 1.45% | – |
| AET | New | AETNA INC NEW | $7,500,000 | – | 92,500 | +100.0% | 1.34% | – |
| STJ | New | ST JUDE MED INC | $6,925,000 | – | 100,000 | +100.0% | 1.24% | – |
| RAD | New | RITE AID CORP | $5,736,000 | – | 800,000 | +100.0% | 1.03% | – |
| ACHC | New | ACADIA HEALTHCARE COMPANY IN | $5,460,000 | – | 120,000 | +100.0% | 0.98% | – |
| MWIV | New | MWI VETERINARY SUPPLY INC | $5,360,000 | – | 37,750 | +100.0% | 0.96% | – |
| CYBX | New | CYBERONICS INC | $4,029,000 | – | 64,500 | +100.0% | 0.72% | – |
| VSAR | New | VERSARTIS INC | $3,484,000 | – | 124,255 | +100.0% | 0.62% | – |
| TNDM | New | TANDEM DIABETES CARE INC | $3,171,000 | – | 195,000 | +100.0% | 0.57% | – |
| RLYP | New | RELYPSA INC | $3,064,000 | – | 126,000 | +100.0% | 0.55% | – |
| CFN | New | CAREFUSION CORP | $3,016,000 | – | 68,000 | +100.0% | 0.54% | – |
| AGN | New | ALLERGAN INC | $2,750,000 | – | 16,250 | +100.0% | 0.49% | – |
| TBPH | New | THERAVANCE BIOPHARMA INC | $1,594,000 | – | 50,000 | +100.0% | 0.29% | – |
| NVDQ | New | NOVADAQ TECHNOLOGIES INC | $1,483,000 | – | 90,000 | +100.0% | 0.27% | – |
| CERU | New | CERULEAN PHARMA INC | $497,000 | – | 85,635 | +100.0% | 0.09% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2014-08-14
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| INTUITIVE SURGICAL INC | 43 | Q2 2024 | 4.0% |
| NEUROCRINE BIOSCIENCES INC | 42 | Q2 2024 | 4.8% |
| PACIRA PHARMACEUTICALS INC | 42 | Q2 2024 | 2.6% |
| ULTRAGENYX PHARMACEUTICAL IN | 42 | Q2 2024 | 2.4% |
| ACADIA HEALTHCARE COMPANY IN | 41 | Q2 2024 | 4.4% |
| ASCENDIS PHARMA A/S | 38 | Q2 2024 | 1.3% |
| BIOMARIN PHARMACEUTICAL INC | 38 | Q2 2024 | 1.3% |
| MACROGENICS INC | 38 | Q2 2024 | 0.5% |
| AMICUS THERAPEUTICS INC | 37 | Q2 2024 | 0.6% |
| ADAPTIMMUNE THERAPEUTICS PLC | 37 | Q2 2024 | 1.2% |
View Rock Springs Capital Management LP's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Travere Therapeutics, Inc. | May 01, 2024 | 4,411,983 | 5.8% |
| Xilio Therapeutics, Inc. | April 05, 2024 | 3,003,259 | 8.7% |
| Aclaris Therapeutics, Inc. | February 14, 2024 | 2,998,495 | 4.2% |
| AGIOS PHARMACEUTICALS, INC. | February 14, 2024 | 2,152,173 | 3.8% |
| Gamida Cell Ltd.Sold out | February 14, 2024 | 0 | 0.0% |
| Immunocore Holdings plc | February 14, 2024 | 2,661,507 | 5.4% |
| Inozyme Pharma, Inc. | February 14, 2024 | 3,681,174 | 6.0% |
| Mereo BioPharma Group plc | February 14, 2024 | 39,919,255 | 5.7% |
| SPRUCE BIOSCIENCES, INC. | February 14, 2024 | 2,609,125 | 6.4% |
| Spyre Therapeutics, Inc.Sold out | February 14, 2024 | 0 | 0.0% |
View Rock Springs Capital Management LP's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| N-PX | 2024-08-30 |
| 13F-HR | 2024-08-14 |
| 13F-HR | 2024-05-15 |
| SC 13G | 2024-05-01 |
| SC 13G/A | 2024-04-05 |
| 13F-HR | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
View Rock Springs Capital Management LP's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.